What is the first‑line treatment for acute bacterial conjunctivitis (pink eye)?

First-Line Therapy for Bacterial Conjunctivitis

For uncomplicated bacterial conjunctivitis, prescribe a topical broad-spectrum antibiotic applied four times daily for 5–7 days, with topical fluoroquinolones (moxifloxacin 0.5% or similar) as the preferred first-line agents due to superior coverage of common pathogens including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. 1

Treatment Selection Algorithm

Standard First-Line Options

• Topical fluoroquinolones are the preferred first-line agents, with fourth-generation options (moxifloxacin 0.5%, gatifloxacin) offering superior gram-positive coverage including activity against some methicillin-resistant S. aureus strains. 1, 2

• No single antibiotic has demonstrated superiority for uncomplicated cases, so selection can be based on dosing convenience, cost, and local resistance patterns. 1

• Alternative broad-spectrum options include polymyxin B/trimethoprim, gentamicin, tetracycline, or ofloxacin 0.3% if fluoroquinolones are unavailable or cost-prohibitive. 1, 3

Dosing Regimen

• Apply one drop four times daily for 5–7 days to achieve earlier clinical and microbiological remission (68% cure rate versus 55% with placebo by days 4–9). 1, 4

• This regimen reduces transmissibility and allows faster return to work or school compared to no treatment. 1, 4

• For improved compliance in young children, simplified three-times-daily regimens (e.g., moxifloxacin) may be considered. 1

Clinical Outcomes and Natural History

• Mild bacterial conjunctivitis is self-limited in immunocompetent patients, with approximately 64% resolving spontaneously by days 6–10 without treatment. 1

• Topical antibiotics accelerate resolution: by days 3–5,62% of antibiotic-treated patients achieve clinical cure versus only 28% with placebo (p < 0.02). 5

• Bacterial eradication occurs in 71% by day 3–5 and 79% by day 8–10 with antibiotics, compared to 19% and 31% with placebo (p < 0.001). 5

Special Populations and Circumstances

Contact Lens Wearers

• Reserve fluoroquinolones (ofloxacin or ciprofloxacin) for contact lens wearers due to higher risk of Pseudomonas aeruginosa infection requiring more aggressive coverage. 2

Suspected MRSA

• MRSA isolates are generally resistant to fluoroquinolones and aminoglycosides but remain susceptible to vancomycin. 1, 2

• Consider compounded topical vancomycin if no response to fluoroquinolones within 48–72 hours, particularly in nursing-home residents or community-acquired cases. 1

Pediatric Patients

• Fluoroquinolones including besifloxacin, levofloxacin, gatifloxacin, ciprofloxacin, moxifloxacin, and ofloxacin are approved for conjunctivitis in children older than 12 months. 1

• Polymyxin B/trimethoprim is effective and well-tolerated in children, with 95% of infected eyes cured or improved within 7 days. 6

Critical Red Flags Requiring Immediate Ophthalmology Referral

Do not prescribe topical antibiotics alone and arrange urgent ophthalmology evaluation if:

• Visual loss or significant change in vision is present 1
• Moderate to severe eye pain (beyond mild irritation) occurs 1
• Corneal involvement (opacity, infiltrate, or ulcer) is evident 1
• Severe purulent discharge suggests gonococcal infection 1
• History of herpes simplex virus eye disease exists 1
• Patient is immunocompromised 1
• No improvement after 3–4 days of appropriate therapy 1, 2

Infections Requiring Systemic Antibiotics (Not Topical Alone)

Gonococcal Conjunctivitis

• Systemic antibiotics are mandatory: ceftriaxone 250 mg IM single dose plus azithromycin 1 g oral single dose for adults. 1

• Obtain conjunctival cultures and Gram staining before initiating treatment. 1

• Daily monitoring until resolution is required to prevent corneal perforation. 1

Chlamydial Conjunctivitis

• Systemic therapy is required: azithromycin 1 g oral single dose or doxycycline 100 mg oral twice daily for 7 days. 1

• More than 50% of affected infants have concurrent infection at other sites (nasopharynx, genital tract, lungs). 1

• Topical antibiotics provide no additional benefit beyond systemic treatment. 2

Common Pitfalls to Avoid

• Do not use topical antibiotics for viral conjunctivitis, as they provide no benefit, may cause ocular toxicity, and promote antimicrobial resistance. 1

• Avoid combination antibiotic-steroid drops (e.g., Tobradex) unless viral etiology—particularly HSV or adenovirus—has been definitively excluded, as steroids can exacerbate viral infections. 1

• Do not prescribe oral antibiotics for routine bacterial conjunctivitis; they are reserved exclusively for gonococcal and chlamydial infections. 1

• Consider sexual abuse in preadolescent children presenting with gonococcal or chlamydial conjunctivitis. 1

Follow-Up Strategy

• Instruct patients to return for evaluation in 3–4 days if no improvement is observed. 1, 2, 4

• At follow-up, perform interval history, visual acuity measurement, and slit-lamp biomicroscopy. 2

• If infection worsens or fails to improve after 48–72 hours, obtain conjunctival cultures and consider resistant organisms. 1

Alternative When Antibiotics Are Unavailable

• Povidone-iodine 1.25% ophthalmic solution may be as effective as topical antibiotics and can be considered when access to antibiotics is limited. 1, 4

Infection Control Measures

• Counsel patients on strict hand hygiene with soap and water, avoiding eye rubbing, using separate towels, and avoiding close contact during the contagious period (7–14 days for viral conjunctivitis). 1